Floy GmbH
AI NativeMaximizing the diagnostic value of routine imaging with artificial intelligence.
Est 2021|Raised $12.8M
Maximizing the diagnostic value of routine imaging with artificial intelligence.
Published Jul 14, 2026
Floy has public statements and press coverage claiming adoption in Germany. These statements provide a narrative of rapid uptake but are not independently audited in the public sources reviewed.
| Starting Price | Not publicly listed (appears custom; press indicates a patient self-pay add-on model) | Not reliably public; enterprise deals are typically custom | Not publicly listed (typically enterprise/custom) |
| Primary use case | Outpatient radiology practices seeking opportunistic screening and a supplementary patient-facing service | Hospital systems prioritizing acute triage and workflow orchestration (module-dependent) | Providers focused on oncology and screening assistance in selected modalities (region- and module-dependent) |
| Key strengths | Distinctive commercial model (patient self-pay add-on); emphasis on opportunistic screening from routine scans; reported adoption in Germany | Established enterprise footprint in many hospital settings; emphasis on workflow integration (varies by module) | Published evidence in selected domains and established presence in several markets |
| Key weaknesses | Limited independent user reviews; limited public enterprise security documentation; certification status appears module-specific and requires validation | Implementation complexity and cost may be substantial; market-wide alert fatigue concerns apply | Pricing transparency limited; regulatory clearances and performance vary by region and module |
—